Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CD19-CD22 CAR-T in R/R B-cell ALL
NCT05223686Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Human CD19-CD22 Targeted T Cells Injection in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limited Toxicity. Status: unknown.
02
Drugs
Human CD19-CD22 Targeted T Cells Injection
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05223686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223686.